This page collects the key figures and concepts from this lesson. Use it as a study reference; HSCI 230, 341, and 410 will assume familiarity with this material.

Key figures introduced in this lesson

A consolidated course glossary will be published on the HSCI 130 index page.

Introduction and Overview

Modern genetics is the work of about 160 years. The pace of change accelerates: monastery garden experiments in the 1860s, the double helix in 1953, the human genome in 2003, gene editing therapies in clinical use by the 2020s. Each generation since 1950 has seen the cost and feasibility of genetic investigation drop by orders of magnitude. The public health implications have evolved accordingly, from population-level eugenics in the early 20th century, through targeted newborn screening from the 1960s, to the contemporary debates over polygenic risk scores and germline gene editing. This section traces the scientific arc.

Mendel and the laws of inheritance

Gregor Mendel (1822–1884) was an Augustinian friar who spent the 1850s and 1860s growing pea plants in the gardens of the Abbey of St. Thomas in Brno (now in the Czech Republic). Mendel was a careful experimentalist who tracked seven discrete traits across thousands of pea plants over multiple generations. His paper, published in 1866 in the proceedings of the Brno Natural History Society, articulated what we now call the laws of segregation and independent assortment. Mendel had identified the basic statistical regularities of inheritance — that traits passed from parent to offspring through discrete factors (now called genes) following predictable ratios. The paper was essentially ignored for 35 years.

The reason for the neglect is partly that Mendel published in a regional natural-history journal with limited circulation, and partly that the scientific establishment of the 1860s was preoccupied with Darwin's On the Origin of Species (1859) and the mechanism of inheritance that Darwin's theory implicitly required. Mendel had provided that mechanism, but his work didn't reach the people who needed it. He was rediscovered nearly simultaneously by three botanists — Hugo de Vries, Carl Correns, and Erich von Tschermak — in 1900. By 1910, Mendelian inheritance had been established for traits in fruit flies (Thomas Hunt Morgan's work at Columbia), and a generation of genetic research could begin in earnest.

The 1900-1953 period was extraordinarily productive. Genes were localized to chromosomes (Morgan, 1910s). Mutations were induced experimentally (Muller, 1927, who showed X-rays cause mutations). Specific human conditions were identified as Mendelian: Huntington disease, sickle cell disease, color blindness, and several others were shown to follow Mendelian inheritance patterns. The chemical nature of the genetic material remained mysterious through the 1920s and 1930s; the assumption was that genes were made of protein, the only known macromolecules complex enough to carry hereditary information. The 1944 Avery-MacLeod-McCarty experiments at the Rockefeller Institute, building on earlier work by Frederick Griffith, demonstrated that DNA — long dismissed as a structurally simple molecule — was actually the genetic material.

The double helix

The race to determine DNA's structure in the early 1950s involved several groups and one of the most contested credit disputes in 20th-century science. The key figures were James Watson (American, 1928–) and Francis Crick (British, 1916–2004) at Cambridge, working largely from theoretical reconstruction; Rosalind Franklin (British, 1920–1958) at King's College London, producing the X-ray diffraction images that revealed the helical structure; and Maurice Wilkins (Northern Irish, 1916–2004), also at King's College, who shared Franklin's images with Watson and Crick without her knowledge or consent.

The April 1953 papers in Nature — three back-to-back papers by Watson & Crick (1953), Wilkins and colleagues, and Franklin and Gosling — established the double-helix structure. The structure was immediately suggestive of a replication mechanism (the two strands separate and each templates a new partner) and a storage mechanism (the linear sequence of base pairs carries information). The 1962 Nobel Prize in Physiology or Medicine was awarded to Watson, Crick, and Wilkins for the discovery. Franklin had died of ovarian cancer in 1958 at age 37; Nobel rules do not allow posthumous awards. Her central contribution to the structure determination — particularly the famous 'Photograph 51' — was substantially underrecognized for decades and is now a standard part of the history of science.

The credit dispute matters for several reasons. It shaped how women in science were perceived and treated for a generation (Franklin's contributions were minimized in Watson's 1968 memoir The Double Helix, which portrayed her as difficult, unfeminine, and intellectually limited — a portrait subsequent historical analysis has thoroughly refuted). It is now a standard case study in scientific ethics regarding credit, collaboration, and the use of others' data without permission. And it illustrates how the canonical history of a scientific discovery can be constructed to favor certain participants over others.

The Human Genome Project

The Human Genome Project was announced in 1990 and completed in 2003 — the 50th anniversary of the Watson-Crick-Franklin papers. The project's goal was to sequence the entire human genome (approximately 3 billion base pairs across 23 chromosome pairs) and to identify all human genes (estimated at the project's start to be around 100,000, now known to be approximately 20,000). The project was a coordinated international effort led by the U.S. National Human Genome Research Institute (Francis Collins, director) and parallel teams in the UK, France, Germany, Japan, and China. A private competitor, Celera Genomics (Craig Venter, founder), pursued a parallel effort with a different methodology and announced essentially simultaneous completion in 2003. The draft sequences were published in February 2001 in parallel papers — the International Human Genome Sequencing Consortium (2001) in Nature and Venter and colleagues (2001) in Science.

The Human Genome Project's substantive findings were both expected and surprising. Expected: most of the genome's basic structure was characterized as predicted. Surprising: humans have far fewer protein-coding genes than expected (~20,000 vs. the predicted ~100,000), and an enormous fraction of the genome (over 98%) is non-protein-coding sequence whose function was initially unclear. The subsequent two decades of work have identified extensive regulatory function in non-coding regions — transcription factor binding sites, non-coding RNAs, chromatin organization features — and the contemporary understanding of the genome is much more dynamic than the 2003 picture suggested.

The project cost approximately US$2.7 billion in 1990-2003 dollars. The infrastructure investment was substantial: the project required developing automated DNA sequencing technology, large-scale data management systems, and international data-sharing agreements. The post-2003 cost collapse has been extraordinary. By 2014, a complete human genome could be sequenced for approximately $1,000. By 2024, the cost was approximately $200-400, with continuing rapid decline. This 'Moore's Law' of sequencing — actually faster than computing's Moore's Law — has driven the entire genomic revolution that followed.

What the cost collapse enables

Sequencing cost collapse changes what genetic research can study. In 2003, sequencing a single genome was a major project. Today, a single laboratory can sequence thousands of genomes per year, and major biobanks operate at the 100,000-1,000,000 genome scale. The UK Biobank's genotyped cohort of 500,000 participants, the All of Us research program targeting 1 million participants in the US, China's biobank initiatives at million-plus scale, and parallel efforts in Iceland (deCODE), Estonia, and elsewhere have produced a population-genomics infrastructure that the founders of the Human Genome Project would have considered fantastical.

What this scale enables: genome-wide association studies (GWAS) can find common variants of small effect for essentially any measurable trait, with sample sizes large enough to overcome the statistical noise inherent in genome-wide testing. Rare-variant analyses can compare cases to large control reference panels to identify rare variants contributing to disease. Cancer genomics can sequence thousands of tumors to identify driver mutations and resistance mechanisms. Population-scale projects can characterize the geographic and demographic distribution of genetic variation. Pharmacogenomics can identify variants that predict drug response and toxicity. Each of these research programs is now standard; in 2003, none of them were feasible at population scale.

The questions being asked are now different from those asked in 2003. Not 'where's the gene for X?' but 'what is the joint distribution of small effects across thousands of variants, and how does that distribution interact with environment, behavior, and life course?' The contemporary frontier is methodologically substantial. Polygenic risk scores (discussed in Section 3) are one product. Pharmacogenomic prescribing systems are another. The mass cancer-genomics enterprise is another. Each raises its own scientific, clinical, and ethical questions, and the field is moving fast enough that 2026's frontier will look different from 2030's. This is one of the parts of public health where things are genuinely changing within career timescales.

Introduction and Overview

Genetics has been used in service of human dignity and in service of state violence. Both stories are part of public health's inheritance. Eugenics — the idea that human populations could and should be 'improved' through selective reproduction — was scientific mainstream in much of Europe and North America from the 1880s through 1945. It was supported by major universities, leading scientists, and progressive politicians of its era. It produced forced sterilization laws across North America, the United States Supreme Court's Buck v. Bell decision, the Nazi T4 program, and ultimately the Holocaust. It also produced Canadian sterilization laws that continued in force until the 1970s, disproportionately affecting Indigenous women. This section walks through the history carefully because it is part of public health's responsibility to remember.

The eugenics movement

The term 'eugenics' was coined by Francis Galton (1822–1911), the polymath cousin of Charles Darwin. Galton was an extraordinary scientist by some measures — he made foundational contributions to statistics, including correlation and regression, and to the early study of human variation — and an authoritarian eugenicist by others. He proposed in the 1880s that human populations could be improved through selective breeding, with 'desirable' traits encouraged and 'undesirable' traits eliminated. The proposal combined statistical sophistication with extraordinarily naive assumptions about the heritability of complex social traits.

The eugenics movement that grew from Galton's proposals dominated mainstream scientific opinion in Europe and North America from roughly 1880 through 1945. Major universities established eugenics departments and research programs. Eugenic ideas were promoted in popular media, in school textbooks, in religious sermons, and in political speeches. The American Eugenics Society organized 'better baby' contests at state fairs, judging infants on health indicators and racial features. The Cold Spring Harbor Eugenics Record Office, founded in 1910, became the institutional center of US eugenic research. Progressive politicians of the era — Theodore Roosevelt, Margaret Sanger (mentioned in Module 5 with appropriate complexity), and many others — supported eugenic principles. The movement was not a fringe view; it was the scientific and political mainstream of its time.

The substantive intellectual content of eugenics was deeply flawed. It assumed that complex traits (intelligence, criminality, mental illness, character) were primarily heritable when in fact they have substantial environmental components. It applied highly questionable measurement instruments (early IQ tests, often administered in conditions that disadvantaged immigrant and minority populations) to identify 'feeble-minded' individuals targeted for sterilization. It ignored the role of poverty, malnutrition, and trauma in producing the conditions it sought to eliminate. And it was thoroughly intertwined with racial and class hierarchies of its time — eugenic sterilization was overwhelmingly applied to poor people, immigrants, racial minorities, and Indigenous people.

Buck v. Bell and US sterilization

In the United States, eugenic forced sterilization laws were enacted in 32 states between 1907 and 1937. Approximately 70,000 Americans were forcibly sterilized under these laws, with state programs continuing in some states into the 1970s. The legal foundation was the 1927 US Supreme Court decision Buck v. Bell, in which Justice Oliver Wendell Holmes Jr. — typically remembered as a progressive jurist — wrote the majority opinion upholding Virginia's sterilization law. Holmes's famous sentence has become canonical: 'Three generations of imbeciles are enough.'

The case involved Carrie Buck, an 18-year-old institutionalized in the Virginia State Colony for Epileptics and Feebleminded. Buck had been raped at 17 and had given birth to a daughter; the state argued she should be sterilized as 'feeble-minded.' Subsequent historical investigation has revealed that Carrie Buck was almost certainly of normal intelligence (her school records show she was an average student before being institutionalized); that her daughter Vivian similarly tested as normal-intelligence before her early death at age 8; and that the case was substantially fabricated by Virginia officials to produce a Supreme Court test case. The 'three generations of imbeciles' that Holmes referenced did not exist in any meaningful sense.

Buck v. Bell has never been overturned. The decision remains good law in the United States, though its specific operational effects have been eliminated by subsequent civil rights legislation. The Nazi defendants at the Nuremberg trials specifically cited Buck v. Bell as legal precedent for their own sterilization programs, which the German Sterilization Law of 1933 had been substantially modeled on US state laws. The US eugenics movement provided technical, legal, and ideological support for Nazi medical policy, with eugenicists like Harry Laughlin receiving honorary degrees from German universities in the early 1930s. This part of the history is uncomfortable and is regularly omitted from popular accounts.

Eugenics in Canada: Alberta and BC

Canadian eugenic sterilization laws are part of the same story, with particular Canadian features. Alberta's Sexual Sterilization Act, enacted in 1928 and not repealed until 1972, authorized forced sterilization of people deemed 'mentally defective' by a four-person Eugenics Board. Approximately 2,800 people were sterilized under the Act over its 44-year operation. The Act was enthusiastically supported by progressive Alberta politicians, including the United Farmers of Alberta government that introduced it and the Social Credit government that operated it for most of its history. Premier Ernest Manning supported the program throughout his tenure (1943-1968).

British Columbia's Sexual Sterilization Act, enacted in 1933 and repealed in 1973, was structurally similar to Alberta's but operated on a smaller scale, with several hundred sterilizations recorded. The Saskatchewan government considered similar legislation in the 1930s but did not enact it. Manitoba operated less-formal sterilization programs through provincial mental health institutions without specific enabling legislation.

The Canadian sterilization programs disproportionately affected specific populations. Indigenous women were targeted at rates far above their proportion of the population — in some Alberta institutions, Indigenous women were the majority of those sterilized despite being a small fraction of the institutional population. Eastern European immigrants, particularly Ukrainian Canadians in Alberta, were heavily represented. Catholic women were sterilized at higher rates than Protestant women. Working-class women were sterilized at higher rates than middle-class women. The programs were not eugenic in some abstract sense; they were eugenic in a specific colonial, racialized, and gendered sense.

The post-1972 reckoning has been slow. Survivors of the Alberta program filed a class-action lawsuit in the 1990s and the Alberta government settled with payments to surviving plaintiffs in 1999. BC's reckoning has been less complete. Forced sterilization of Indigenous women in Canadian healthcare settings — not under the specific sterilization acts, but in regular hospital and clinical settings — has continued to be documented through the 2000s and 2010s. The most recent cases of coercive sterilization of Indigenous women in Saskatchewan and other provinces, documented by the Saskatchewan Senator Yvonne Boyer and journalist Karen Stote, suggest the practice is not entirely historical. Class-action litigation is ongoing.

Nazi medicine and the post-war framework

Nazi Germany took eugenic thinking to its conclusion. The German Sterilization Law of 1933 was modeled in part on US state laws and authorized sterilization for 'genetic' conditions including 'feeblemindedness,' schizophrenia, and chronic alcoholism. Over 400,000 Germans were forcibly sterilized between 1934 and 1945. The 1939-1945 T4 program — named for the address of its headquarters at Tiergartenstrasse 4 in Berlin — murdered approximately 200,000-300,000 disabled people in German psychiatric institutions, including children. The personnel and techniques developed in the T4 program were subsequently deployed in the Holocaust. The continuity between eugenic medical practice and genocide is direct, not metaphorical.

The post-war reckoning produced the Nuremberg Code (1947), drafted as part of the Nuremberg Doctors' Trial that prosecuted Nazi medical personnel. The Code articulated principles for research with human subjects, including the requirement of voluntary informed consent, scientific justification, and proportionate risk-benefit ratios. The Nuremberg Code is the founding document of modern research ethics and is the conceptual ancestor of the Belmont Report (Module 5) and contemporary research ethics frameworks. It was a direct response to the medical experiments Nazi physicians had conducted on concentration camp inmates — experiments that were extensively documented and prosecuted.

Most eugenic laws in industrialized countries were repealed after WWII, though the repeal was uneven. Alberta's law remained in force for 27 years after the Nuremberg Code. Sweden's compulsory sterilization continued, in modified form, until 1976. North Carolina conducted eugenic sterilizations into the 1970s. Several US states paid reparations to victims in the 2000s and 2010s. The historical reckoning continues.

Why eugenic history matters now

Two reasons make this history mandatory for any public health student. First, eugenics was not pseudoscience operating outside mainstream public health — it was part of it, with leading figures of the field actively participating. Forgetting this allows the field to imagine itself as innocent. Second, contemporary genetic medicine raises analogous questions in updated forms. Prenatal screening for Down syndrome, with most pregnancies in which Down syndrome is detected being terminated, raises questions about population-level reduction of conditions that are also identities and communities. Embryo selection through preimplantation genetic diagnosis raises questions about which conditions should be 'selected against.' Gene editing of human germline cells (the 2018 He Jiankui case in China being the high-profile boundary-violation) raises questions about heritable modifications. Polygenic embryo screening — increasingly offered commercially — raises questions about which traits should be 'optimized.'

None of these contemporary debates have settled answers. They have answers that have to be argued for, not assumed. The historical context — knowing how respectable scientific opinion in 1925 endorsed practices that we now recognize as horrific — should produce caution about confident contemporary judgments that this generation has solved the underlying ethical questions.

The contemporary mainstream view in medical genetics distinguishes between individual reproductive choice (protected, with autonomy framing) and state-imposed reproductive policy (rejected, as the eugenic legacy makes clear). The boundary is sometimes harder to draw in practice than in principle. The contemporary work of the disability rights movement — particularly Alison Kafer, Rosemarie Garland-Thomson, and others — has produced sophisticated critique of prenatal screening practices that don't repeat the explicit coercion of historical eugenics but produce population-level effects that disability advocates argue are continuous with eugenic aims. The disability rights critique is worth engaging with seriously rather than dismissing.

Introduction and Overview

The popular framing of 'the gene for X' is misleading for almost every disease. Understanding why requires distinguishing two very different kinds of genetic causation — and the contemporary research tools that work with each. This section walks through Mendelian disease (single-gene, high-penetrance, often rare), polygenic disease (many genes with small effects, the architecture of most chronic conditions), the heritability concept (and its frequent misinterpretation), and the polygenic risk score era.

Mendelian conditions

A small number of human diseases follow single-gene Mendelian inheritance: cystic fibrosis (CFTR gene mutations), Huntington disease (HTT trinucleotide repeats), sickle cell disease (β-globin mutations), phenylketonuria (PAH mutations), BRCA1/BRCA2-associated cancer syndromes, familial hypercholesterolemia (LDLR and related), and several thousand others. For these conditions, a specific genotype produces the disease with high penetrance (proportion of carriers who develop the condition) — though not 100% in most cases, and modified by other genes and environment.

Mendelian conditions are individually rare but collectively important. There are approximately 7,000 known Mendelian diseases, and approximately 5-7% of the population carries a recognized pathogenic variant for one of them. Newborn screening (Section 4) targets a subset of Mendelian conditions for which early detection enables effective intervention. Carrier screening programs for autosomal recessive conditions (Tay-Sachs in Ashkenazi Jewish populations, sickle cell in African-descent populations (the protective heterozygote-malaria balance described by Allison, 1954), cystic fibrosis in Northern European-descent populations, thalassemias in Mediterranean and South Asian populations) have been operationalized in some health systems.

Mendelian conditions have driven much of the success of genetic medicine. The first FDA-approved gene therapies have been for Mendelian conditions: Luxturna (2017, for Leber congenital amaurosis), Zolgensma (2019, for spinal muscular atrophy), Casgevy (2023, the first CRISPR-based therapy, for sickle cell disease and beta-thalassemia). These therapies are extraordinarily expensive (Zolgensma is approximately $2.1 million per dose), raising fundamental access and equity questions. The technical feasibility of correcting single-gene conditions has substantially outrun the policy infrastructure for making the treatments available to those who need them.

Complex (polygenic) conditions

Most chronic diseases — type 2 diabetes, coronary heart disease, schizophrenia, major depression, most cancers, most autoimmune diseases, hypertension, asthma, type 1 diabetes, ADHD, autism spectrum disorder — are polygenic. Hundreds to thousands of common genetic variants each contribute a tiny amount of risk, and environment matters as much as or more than genetics. There is no 'gene for type 2 diabetes' in any clinically meaningful sense, despite popular framings to the contrary.

The methodology that has enabled polygenic disease research is the genome-wide association study (GWAS). A GWAS genotypes large samples of cases and controls at hundreds of thousands or millions of common genetic variants (typically single-nucleotide polymorphisms, SNPs), then statistically identifies variants associated with the disease. The first GWAS was published in 2005 (for age-related macular degeneration); by 2026, GWAS have been conducted for essentially every measurable trait, with sample sizes routinely in the hundreds of thousands and increasingly in the millions.

The findings of polygenic GWAS have been consistent across traits: many variants of small effect, distributed across the genome, with the cumulative effect of any single variant typically explaining less than 0.1% of population variance. For most chronic diseases, the combined effect of all identified GWAS variants explains a substantial but minority fraction of heritability (typically 20-50%), with the remaining 'missing heritability' attributable to rare variants, gene-environment interactions, structural variants, and other factors that GWAS methodology doesn't capture well.

Heritability and its frequent misinterpretation

Heritability is the proportion of variance in a trait, in a given population, that can be attributed to genetic variance. The largest meta-analysis of twin studies to date (Polderman et al., 2015) examined 17,804 traits across 50 years of twin research and reported an average heritability of approximately 49%. The standard misinterpretation: 'height is 80% heritable, therefore your height is 80% determined by genetics.' This is wrong, and it is one of the single most consequential misinterpretations in popular health science.

Heritability is a population statistic, not an individual decomposition. It depends on the environment of the population studied. The heritability of height can be high in one country and low in another based on nutritional variation: when nutrition is uniformly good, most height variation reflects genetic differences (high heritability); when nutrition is highly variable, more height variation reflects environmental differences (lower heritability). The same gene, the same person, would produce different heritability estimates depending on which population is being measured. The statistic tells you about the distribution of causes of variation in a population, not about the causes of any individual's trait value.

Heritability does not mean a trait is unmodifiable. The classical example is phenylketonuria — a single-gene Mendelian condition with extremely high heritability that is essentially completely modifiable through dietary phenylalanine restriction. The condition is 'genetic' in every sense, and yet the difference between catastrophic intellectual disability and normal development is determined entirely by diet. Heritability is silent on the question of whether environmental intervention works.

Heritability also does not have any direct interpretation for between-group differences. The classical example here is height differences between populations: heritability of height is high within most populations, but a substantial fraction of between-population height differences over the past century has been driven by nutritional improvements rather than genetic change. The same logic applies to other traits where between-group differences have been wrongly attributed to genetic causes. Within-group heritability tells you nothing — literally nothing — about between-group differences. This is a technical statistical point but it is the foundation of a huge amount of careful contemporary work on race, ancestry, and genetics, and it is consistently misunderstood in popular discourse.

Polygenic risk scores and the equity problem

A polygenic risk score (PRS) combines effects across many GWAS-identified variants to produce a single risk estimate for an individual (Khera et al., 2018). PRS for cardiovascular disease, type 2 diabetes, several cancers, schizophrenia, and many other conditions have been developed and are being explored for clinical use. The basic appeal is intuitive: instead of treating everyone as having average population risk, identify high-risk individuals for targeted screening, prevention, or intervention.

PRS are improving rapidly but remain limited in several important ways. Predictive accuracy is modest. Even the best PRS typically improve risk prediction only marginally over conventional risk factors. A 'high PRS' for type 2 diabetes typically shifts your absolute risk modestly (perhaps from 10% lifetime risk to 15% lifetime risk), not dramatically. Predictive accuracy is unequal across populations. Because most GWAS data are from European-ancestry cohorts, PRS perform substantially worse in non-European-ancestry populations — by some estimates, 2-5× worse (Martin et al., 2019). Deploying PRS clinically before this gap is closed risks widening, not narrowing, health disparities.

Clinical actionability is unclear. Telling someone they have high genetic risk for a condition for which they should already be doing the recommended preventive behaviors (eat well, exercise, don't smoke) provides limited new information and may produce fatalism or motivation, depending on the person and the framing. The evidence base for PRS-guided interventions affecting outcomes is much weaker than the evidence base for PRS predicting outcomes. Privacy and discrimination concerns are real. PRS data, like all genetic data, raises questions about insurance discrimination, employment discrimination, and family privacy. The Canadian Genetic Non-Discrimination Act (2017) provides protections in some contexts but the legal landscape is still developing.

The contemporary consensus among medical geneticists is that PRS are scientifically real and useful, that their clinical deployment requires careful attention to performance characteristics in the deploying population, and that the equity concerns are substantial. Several major Canadian PRS research initiatives (including projects within the Canadian Cancer Trials Group and through several provincial health authorities) are explicitly addressing these concerns through diverse-ancestry recruitment and population-specific PRS validation.

Introduction and Overview

The translation of genetics into public health practice has been most successful in two specific areas: newborn screening for Mendelian conditions (operational since 1962 and one of public health's quiet successes) and oncology precision medicine (where targeted therapies based on tumor genetics have transformed cancer care over the past two decades). The translation has been much more uneven for general adult chronic disease, where the precision-medicine promise has consistently outrun delivery. Meanwhile, direct-to-consumer genetic testing has created a parallel infrastructure that operates largely outside medical oversight. This section walks through these three landscapes.

Newborn screening: public health genetics that works

Newborn screening began in 1962 when American microbiologist Robert Guthrie developed a bacterial inhibition assay for phenylalanine that could detect phenylketonuria (PKU) from a heel-prick blood spot. PKU is an autosomal recessive Mendelian condition: affected infants lack a functional enzyme to metabolize phenylalanine, accumulate this amino acid to toxic levels, and develop severe intellectual disability if untreated. PKU, detected within the first few days of life and treated with a phenylalanine-restricted diet, allows essentially normal development. Untreated PKU produces catastrophic, irreversible neurological damage.

The Guthrie test transformed PKU from a devastating childhood condition into a manageable dietary condition. Mass newborn screening for PKU spread rapidly. By 1970, all 50 US states had mandatory PKU screening. Canadian provinces followed through the 1960s and 1970s. Today, every newborn in Canada is screened for 20-30 conditions (the number varies by province), most of them rare metabolic or endocrine disorders for which early detection enables effective intervention.

The conditions screened for typically share four features: (1) the condition is serious without treatment; (2) it has a recognizable preclinical phase that screening can detect; (3) effective treatment is available and improves outcomes when initiated early; (4) the screening test has acceptable accuracy and is feasible at population scale. The Wilson-Jungner criteria for screening (1968) articulate these and several other requirements. Not all serious genetic conditions meet these criteria; conditions for which no effective intervention exists, or for which screening would not detect cases sooner than clinical presentation, are typically not included in newborn screening panels.

The program detects roughly 1 affected infant per 1,000 screened across the panel of conditions. The annual yield in Canada is hundreds of cases of preventable disability. The infrastructure is institutional and quiet: a heel-prick on day 1-3 of life, sent to a provincial laboratory, processed automatically, with positive results triggering immediate follow-up. Most parents in Canada don't know it happened. Newborn screening is one of public health's quietest successes — Mendelian genetics translated into population health practice with minimal political contestation and substantial measurable benefit.

Precision medicine: real in oncology, slower elsewhere

Precision medicine — sometimes called personalized medicine — is the idea that prevention and treatment should be tailored to the individual based on genetic, biomarker, and clinical data. The construct has been heavily promoted since the launch of the US Precision Medicine Initiative in 2015 (renamed the All of Us Research Program in 2016) and has substantial research investment in Canada and globally.

In oncology, precision medicine is real and transformative. HER2 testing in breast cancer (since the 1990s) identifies tumors that respond to trastuzumab (Herceptin) and related agents — transforming HER2-positive breast cancer outcomes. EGFR testing in lung cancer identifies tumors that respond to specific targeted therapies. BRCA testing identifies women at substantially elevated risk for breast and ovarian cancer who may benefit from prophylactic surgery, intensive screening, or PARP inhibitor therapy. Microsatellite instability (MSI) testing in colorectal and other cancers identifies tumors responsive to immune checkpoint inhibitors. Comprehensive tumor genomic profiling is now standard in many advanced cancer cases.

Outside oncology, the precision medicine revolution has been slower than promised. For most chronic diseases, the strongest interventions remain population-level and not genetically tailored. Cardiovascular prevention is more about blood pressure, cholesterol, and behavior than about genetic profile. Type 2 diabetes prevention is more about diet, weight, and activity than about polygenic risk. Mental health treatment selection remains largely empirical rather than precision-guided. The slower outside-oncology progress reflects the simpler genetics of cancer (where tumors often have driver mutations that targeted therapies can hit) compared with the messier polygenic landscape of most chronic disease.

The risk of precision medicine rhetoric is that it pulls resources away from population health toward expensive personalized interventions with smaller aggregate impact. A perfect cardiovascular precision medicine program would produce modest population-level effects compared with what could be achieved by reducing tobacco use, improving diet quality, increasing physical activity, and managing blood pressure — all of which work at population scale and don't require individual genetic testing. The opportunity cost of precision medicine investment is the population-health investment foregone. This is a recurring tension that the field has not adequately addressed.

Epigenetics: bridging gene and environment

Epigenetics studies heritable changes in gene expression that do not involve changes in DNA sequence (Jirtle & Skinner, 2007). The most-studied epigenetic mechanisms are DNA methylation (the addition of methyl groups to cytosine bases, generally silencing nearby gene expression), histone modifications (alterations to the proteins that package DNA, affecting which genes are accessible), and non-coding RNAs (RNA molecules that regulate gene expression without coding for proteins). Each mechanism has been characterized in detail in the past two decades and is now central to understanding development and disease.

The public health significance of epigenetics is twofold. First, epigenetic marks respond to environment (diet, stress, toxin exposure, social conditions) and can persist long after the environmental exposure ends. This provides a mechanistic pathway by which experience can leave biological traces — the missing link, in some accounts, between social determinants and biological outcomes. The Dutch Hunger Winter cohort (Module 6) has been studied epigenetically and shows persistent methylation differences in people exposed in utero. Second, some epigenetic marks can be transmitted across generations, opening the possibility of transgenerational effects of environmental exposure — a finding extensively documented in animal models and increasingly characterized in humans.

The field has been overhyped. Popular claims about epigenetics — 'your trauma is in your DNA,' 'your grandparents' experiences shape your gene expression,' 'you can edit your epigenome through meditation' — are oversimplifications that obscure the complexity of what the actual research shows. Most epigenetic marks turn over rapidly. Most transgenerational effects in humans are small. Most environment-epigenetics-disease pathways are correlational rather than causal. But the core science is real and is reshaping how the gene-environment boundary is understood. Epigenetic clocks (Horvath's age estimators, GrimAge, PhenoAge) are increasingly used as biological-age measures in aging research. Epigenetic biomarkers of exposure (smoking, alcohol, particulate matter) are being developed as objective measures that complement self-report. The translation into public health practice is at an early stage but is unambiguously coming.

Direct-to-consumer genetic testing

Companies like 23andMe (founded 2006), AncestryDNA (launched 2012), and MyHeritage have given millions of consumers access to their own genetic data. The DTC market is now substantial — over 30 million people have used commercial genetic testing services. The clinical utility of the testing is mixed: ancestry information is reasonably accurate, single-gene tests for known variants are accurate when validated, but health-risk predictions vary widely in quality and are typically limited to a small subset of recognized variants.

The clinical questions about DTC testing — does the testing actually improve health outcomes? — have been less prominent than the privacy and policy questions, which are sharper. DTC companies build genetic databases that have been used in research (millions of consenting participants have contributed to research data; not all consent processes have been adequate), in law enforcement (the 2018 identification of the Golden State Killer through a public genealogy database, GEDmatch, was a watershed moment that has been followed by hundreds of subsequent cold-case identifications), and increasingly for commercial purposes (pharmaceutical company partnerships, targeted marketing).

The Canadian legal framework was substantially improved by the Genetic Non-Discrimination Act (GNDA), passed in 2017. The GNDA prohibits insurance companies and employers from requiring or using genetic test results, with criminal penalties for violations. The Act survived a 2020 Supreme Court of Canada constitutional challenge. It does not, however, address all genetic privacy concerns: it doesn't regulate what DTC companies do with the data, doesn't restrict law enforcement use of genealogy databases, and doesn't address the privacy of relatives who can be identified through a single family member's genetic test.

The 23andMe data breach of 2023 — in which the genetic data and ancestry information of millions of users was accessed by attackers — illustrated the privacy stakes. Subsequent class-action litigation has produced settlements. The company filed for bankruptcy in 2025, raising questions about what happens to genetic data when a DTC company fails financially. The contemporary advice from medical geneticists to consumers is generally: be cautious about DTC testing, get genetic counseling from a qualified clinician for any results you act on, and recognize that the privacy implications extend beyond yourself to your biological relatives.

Bringing It All Together

This lesson has walked you through the full arc of the topic across all four sections. As you complete this final assessment, draw on each section to consolidate what you have learned and to prepare for the lessons that build on it.

The list below distills the core ideas the rest of the course will keep coming back to. Read them as a checklist: if any feel unfamiliar, jump back into the relevant section before you take the assessment, since later lessons will assume each of them as common ground.

Data Spotlight

Forward Link

Gene-environment interaction returns as a methodological theme in HSCI 410. The historical and conceptual frame here lets you read those analyses without overclaiming what genetics explains. HSCI 341 will cover the specific statistical methods used in GWAS and polygenic risk score construction. HSCI 130 gives you the substantive and ethical grounding.

Final Reflection

Comprehensive Knowledge Check

This 15-question assessment covers all four sections of Lesson 7. Aim for at least 12 of 15 correct. You may retry until you reach mastery.